Radiopharmaceutical Therapy Frequently Asked Questions (FAQ)

WHAT IS XOFIGO?


Xofigo is Radium 223 Dichloride and is an alpha particle-emitting radioactive therapeutic agent. It is used for treatment of patient with prostate cancer.




WHO IS XOFIGO SUITABLE FOR?


Xofigo is suitable for metastatic castration-resistant prostate cancer (mCRPC) patient on second-generation hormonal therapy has: • Bone metastases, and no visceral metastases • Suspected disease progression: — Increase in biomarker levels, such as prostate-specific antigen (PSA) and/or alkaline phosphatase (ALP) — Progression seen on imaging scans — Emerging symptoms (use of analgesics)




HOW LONG IS THE XOFIGO TREATMENT?


• Treatment plan: 6 injections total • Slow intravenous (IV) injection over 1 minute • Treatment can be completed in 5 months • Patients may return home after the injection




WHAT DO I NEED TO BRING FOR TREATMENT?


ID and/or Passport.
This original Preparation Instruction Sheet
Previous/recent relevant reports or CD, if available.
Previous / recent blood test results, if available.

DO NOT bring valuable belongings, including jewellery, etc SPECIAL ARRANGEMENT If patients are on wheel chair / trolley, please come with:

  • Accompanying staff nurse familiar with patients' medical background
  • Existing IV line / cannula, if any
  • Urine bag, where applicable, should be emptied.
  • Parking for ambulances are available at Level B2 carpark.

Urinal / bedpan / extra diapers when necessary for toileting care.





© 2019 VervEndeavour Pte Ltd. All rights reserved.